A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat

References

• Ahmed S, Kishikawa N, Ohyama K, et al. (2009). Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with photosensitization reaction followed by chemiluminescence detection. Talanta 78:94–100
   PubMed Web of Science ®Google Scholar
• Arola OJ, Saraste A, Pulkki K, et al. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60:1789–92
   PubMed Web of Science ®Google Scholar
• Bottone AE, Voest EE, de Beer EL. (1998). Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment. Clin Cancer Res 4:1031–7
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT. (2010). Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovas Dis 53:121–9
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Martinoni A, et al. (2000). Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517–22
   PubMed Web of Science ®Google Scholar
• Clements IP, Davis BJ, Wiseman GA. (2002). Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation. Nucl Med Commun 23:521–7
   PubMed Web of Science ®Google Scholar
• DiFrancesco R, Griggs JJ, Donnelly J, DiCenzo R. (2007). Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B, Analyt Technol Biomed Life Sci 852:545–53
   PubMed Web of Science ®Google Scholar
• Guglin M, Aljayeh M, Saiyad S, et al. (2009). Introducing a new entity: chemotherapy-induced arrhythmia. Europace 11:1579–86
   Google Scholar
• Hamed S, Barshack I, Luboshits G, et al. (2006). Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27:1876–83
   PubMed Web of Science ®Google Scholar
• Holinski S, Knebel F, Heinze G, et al. (2011). Noninvasive monitoring of cardiac function in a chronic ischemic heart failure model in the rat: assessment with tissue Doppler and non-Doppler 2D strain echocardiography. Cardiovas Ultrasound 9:15 . doi:10.1186/1476-7120-9-15
   PubMed Web of Science ®Google Scholar
• Hongkan W, Soongswang J, Veerakul G, et al. (2009). N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients. J Med Assoc Thailand 92:1450–7
   PubMedGoogle Scholar
• Kelishomi RB, Ejtemaeemehr S, Tavangar SM, et al. (2008). Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 243:96–104
   PubMed Web of Science ®Google Scholar
• Kim YH, Park SM, Kim M, et al. (2012). Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicol Mech Methods 22:488–98
   PubMed Web of Science ®Google Scholar
• Liu B, Li H, Qu H, Sun B. (2006). Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. J Biochem Mol Biol 39:759–65
   PubMedGoogle Scholar
• Lowbeer C, Kawakami T, Tahepjld P, et al. (2002). Importance of preanalytical handling of samples for measurement of cardiac troponin T in coronary effluent from isolated rat hearts. Scand J Clin Lab Invest 62:255–62
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS. (1990). Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076–86
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS, Brenner DE, et al. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585–9
   PubMed Web of Science ®Google Scholar
• Panjrath GS, Patel V, Valdiviezo CI, et al. (2007). Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 49:2457–64
   PubMed Web of Science ®Google Scholar
• Platel D, Pouna P, Bonoron-Adele S, Robert J. (2000). Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Appl Pharmacol 163:135–40
   PubMed Web of Science ®Google Scholar
• Robert J. (2007). Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 23:27–37
   PubMed Web of Science ®Google Scholar
• Sandri MT, Cardinale D, Zorzino L, et al. (2003). Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 49:248–52
   PubMed Web of Science ®Google Scholar
• Teraoka K, Hirano M, Yamaguchi K, Yamashina A. (2000). Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2:373–8
   PubMed Web of Science ®Google Scholar